CBIO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (31 Oct 2023 @ 04:00):

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation...

Stats
今日成交量	460 710
平均成交量	437 269
市值	19.42M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0.240 ( 2023-01-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0247
ATR14	$0.0370 (7.24%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Luo Ying	Buy	3 350 897	Stock Option (Right to Buy)
2023-10-30	Luo Ying	Buy	2 840 376	Common Stock
2023-11-20	Luo Ying	Buy	2 262 755	Stock Option (Right to Buy)
2023-11-20	Ye Weiguo	Buy	1 665 115	Stock Option (Right to Buy)
2023-11-20	Ma Songjiang	Buy	4 510 047	Stock Option (Right to Buy)

INSIDER POWER
24.70
Last 85 transactions
Buy: 88 748 347 \| Sell: 111 334 812

音量相关性

長: -0.02 (neutral)

短: -0.30 (neutral)

Signal:(55.246) Neutral

Catalyst Biosciences Inc 相关性

10 最正相关
CALA	0.925
ODT	0.917
UPC	0.909
BCAB	0.908
NBIX	0.897
LLNW	0.891
ENNV	0.891
LFMD	0.891
YJ	0.889
XPDI	0.889

10 最负相关
SHC	-0.922
WYNN	-0.921
DSPG	-0.917
ACLS	-0.913
PPD	-0.908
BNIX	-0.907
DUNE	-0.906
RVNC	-0.902
HHGC	-0.901
FWONK	-0.899

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Catalyst Biosciences Inc 相关性 - 货币/商品

0.56
( weak )

0.55
( weak )

0.00
( neutral )

0.36
( neutral )

-0.59
( weak negative )

-0.34
( neutral )

Catalyst Biosciences Inc 财务报表

Annual	2022
营收:	$794 000
毛利润:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2022
营收:	$794 000
毛利润:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2021
营收:	$0.00
毛利润:	$-7.38M (0.00 %)
EPS:	$-2.87

FY	2020
营收:	$20.95M
毛利润:	$11.79M (56.26 %)
EPS:	$-2.93

Financial Reports:

No articles found.

Catalyst Biosciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.430 (N/A)	$0 (N/A)	$0.240 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Catalyst Biosciences Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0.994 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$59.77	2015-08-20
Last Dividend	$0.240	2023-01-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$61.44	--
Avg. Dividend % Per Year	39.53%	--
Score	4.37	--
Div. Sustainability Score	0
Div.Growth Potential Score	0.994
Div. Directional Score	0.460	--

Next Divdend (Est)
(2027-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

4.37

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2015	$59.77	22.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$1.430	143.00%
2023	$0.240	41.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	55.72	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	-0.709	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	12.04	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	-0.289	-1.000	-2.89	2.89	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-71.39	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
freeCashFlowPerShareTTM	-0.352	2.00	-0.176	-0.352	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	3.15	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	55.75	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	-0.0127	0.800	-3.42	-2.73	[0.5 - 2]
Total Score				-0.0749

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.439	1.000	-0.145	0	[1 - 100]
returnOnEquityTTM	12.04	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.352	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
payoutRatioTTM	-0.289	1.500	-2.89	2.89	[0 - 1]
pegRatioTTM	-0.0114	1.500	-3.41	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	16.85	1.000	10.00	0	[0.1 - 0.5]
Total Score				0.994

Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.